侯雅昕, 于晓玲, 韩治宇, 刘方义, 赵文鹏, 李华蓉. 125I粒子联合高强度聚焦超声治疗肝癌门静脉癌栓的疗效评价[J]. 解放军医学院学报, 2015, 36(5): 444-446,封三. DOI: 10.3969/j.issn.2095-5227.2015.05.010
引用本文: 侯雅昕, 于晓玲, 韩治宇, 刘方义, 赵文鹏, 李华蓉. 125I粒子联合高强度聚焦超声治疗肝癌门静脉癌栓的疗效评价[J]. 解放军医学院学报, 2015, 36(5): 444-446,封三. DOI: 10.3969/j.issn.2095-5227.2015.05.010
HOU Yaxin, YU Xiaoling, HAN Zhiyu, LIU Fangyi, ZHAO Wenpeng, LI Huarong. Therapeutic effect of hepatocellular carcinoma portal vein tumor thrombus treated by 125I particles implantation combined with high intensity focused ultrasound therapy[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2015, 36(5): 444-446,封三. DOI: 10.3969/j.issn.2095-5227.2015.05.010
Citation: HOU Yaxin, YU Xiaoling, HAN Zhiyu, LIU Fangyi, ZHAO Wenpeng, LI Huarong. Therapeutic effect of hepatocellular carcinoma portal vein tumor thrombus treated by 125I particles implantation combined with high intensity focused ultrasound therapy[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2015, 36(5): 444-446,封三. DOI: 10.3969/j.issn.2095-5227.2015.05.010

125I粒子联合高强度聚焦超声治疗肝癌门静脉癌栓的疗效评价

Therapeutic effect of hepatocellular carcinoma portal vein tumor thrombus treated by 125I particles implantation combined with high intensity focused ultrasound therapy

  • 摘要: 目的 评价放射性125I粒子植入联合高强度聚焦超声治疗肝癌门静脉癌栓的临床疗效。 方法 选取我院2011年3月-2013年10月收治的不同程度肝癌门静脉癌栓患者19例,行125I粒子联合高强度聚焦超声治疗。125I放射性剂量为80~120Gy,单个粒子剂量为0.5 mCi ;高强度聚焦超声:频率0.85 mHz,总治疗时间33~70 min,平均辐照功率300~400 w。对疗效及不良反应进行1~30个月的随访评估,评价治疗前后癌栓大小的变化、术后并发症及患者生存率等。 结果 19例顺利完成治疗,未发生术后大出血、癌栓脱落及急性肝功能衰竭等严重并发症,术后1个月复查,癌栓均有不同程度缩小。随访1~30个月,生存期3~26个月。1年、2年生存率分别为47.4%(n=9)、21.1%(n=4),平均生存期为(11.6±3)个月,Ⅰ、Ⅱ、Ⅲ级中位生存期分别为13.5个月、7个月、4个月。 结论 125I粒子联合高强度聚焦超声治疗肝癌门静脉癌栓,局部疗效明显、创伤小、并发症发生率低,是一种简单、安全、有效的治疗方法。

     

    Abstract: Objective To evaluate the therapeutic effect of hepatocellular carcinoma (HCC) portal vein tumor thrombus (PVTT) treated by 125I particles implantation combined with high intensity focused ultrasound (HIFU) therapy. Methods Nineteen patients with hepatocellular carcinoma portal vein tumor thrombus in different grading who underwent 125I particles implantation combined with HIFU therapy in our hospital from March 2011 to October 2013 were enrolled in our study. The 125I radioactive dose was 80-120 Gy, single particle radioactive dose was 0.5 mCi; HIFU:the frequency was 0.85 MHz, the total treatment time was 33-70 min, and the irradiation power was at an average of 300-400 w. 1-30 months of follow-up evaluation was made concerning the curative effect and adverse reaction, the tumor emboli size changes before and after treatment, postoperative complications and survival rate of the patients. Results All patients had undergone complete treatment, there was no postoperative bleeding, cancer plug and severe complications such as acute liver failure. After 1 month's review, all tumor embolus shrank to different extent. Following-up was done 1 to 30 months with the survival time of 3-26 months. 1- and 2-year survival rate were 47.4% (n=9) and 21.1% (n=4), and the average survival period was (11.6±3) months, level Ⅰ, Ⅱ, Ⅲ median survival were 13.5, 7, 4 months, respectively. Conclusion The local curative effect of 125I implantation combined with high intensity focused ultrasound in treatment of hepatocellular carcinoma with portal vein tumor thrombus is obvious, with small trauma and low complication rate. It is a simple, safe and effective treatment.

     

/

返回文章
返回